Home Science & Medicine Targeted Therapy

Targeted Therapy

Feature articles about advances and current developments in targeted therapy that have significant impact or impact potential on thoracic oncology.

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

By Heather Wakelee, MD For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage...

ALK Testing in Europe

By Enriqueta Felip, MD, PhD ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with stage IV...

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary...

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...

By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the...

The Lung Master Protocol (Lung-MAP)

By Vassiliki A. Papadimitrakopoulou, MD Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...

Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...

By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...

Q & A with Yi-Long Wu, MD

What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally? Current Chinese Lung Cancer Diagnosis...

Meeting News